Anon. n.d. ‘Sodium Oxybate: A Primer for Pharmacists in the Treatment of Narcolepsy’. Retrieved (https://www.researchgate.net/profile/Kimberley_Begley2/publication/265473606_Sodium_Oxybate_A_Primer_for_Pharmacists_in_the_Treatment_of_Narcolepsy/links/54dceb110cf25b09b912dd40.pdf).
Atwood, Brady K., Alex Straiker, and Ken Mackie. 2012. ‘CB2: Therapeutic Target-in-Waiting’. Progress in Neuro-Psychopharmacology and Biological Psychiatry 38(1):16–20. doi: 10.1016/j.pnpbp.2011.12.001.
Balon, Richard. 2006. ‘Mood, Anxiety, and Physical Illness: Body and Mind, or Mind and Body?’ Depression and Anxiety 23(6):377–87. doi: 10.1002/da.20217.
Brisbare-Roch, Catherine. 2007. ‘Promotion of Sleep by Targeting the Orexin System in Rats, Dogs and Humans’. 13(2):150–55.
Carlos H. Schenck, Mark W. Mahowald. 2005. ‘Insights from Studying Human Sleep Disorders’. 437(7063):1279–85.
Carvalho, Ana Franky, and Elisabeth J. Van Bockstaele. 2012. ‘Cannabinoid Modulation of Noradrenergic Circuits: Implications for Psychiatric Disorders’. Progress in Neuro-Psychopharmacology and Biological Psychiatry 38(1):59–67. doi: 10.1016/j.pnpbp.2012.01.008.
Cera, Nicoletta, Armando Tartaro, and Stefano L. Sensi. 2014. ‘Modafinil Alters Intrinsic Functional Connectivity of the Right Posterior Insula: A Pharmacological Resting State fMRI Study’. PLoS ONE 9(9). doi: 10.1371/journal.pone.0107145.
Cryan, John F., and Klemens Kaupmann. 2005. ‘Don’t Worry “B” Happy!: A Role for GABAB Receptors in Anxiety and Depression’. Trends in Pharmacological Sciences 26(1):36–43. doi: 10.1016/j.tips.2004.11.004.
Eric J. Olson, Kannan Ramar. 2013. ‘Management of Common Sleep Disorders’. 88(4):231–38.
Freund, Tamás F. 2003. ‘Interneuron Diversity Series: Rhythm and Mood in Perisomatic Inhibition’. Trends in Neurosciences 26(9):489–95. doi: 10.1016/S0166-2236(03)00227-3.
H. Attarian, O. Adenuga. n.d. ‘Treatment of Disorders of Hypersomnolence’. 16(9):302–302.
Hill, Andrew J., Claire M. Williams, Benjamin J. Whalley, and Gary J. Stephens. 2012. ‘Phytocannabinoids as Novel Therapeutic Agents in CNS Disorders’. Pharmacology & Therapeutics 133(1):79–97. doi: 10.1016/j.pharmthera.2011.09.002.
Holmes, Andrew, Markus Heilig, Nadia M. J. Rupniak, Thomas Steckler, and Guy Griebel. 2003. ‘Neuropeptide Systems as Novel Therapeutic Targets for Depression and Anxiety Disorders’. Trends in Pharmacological Sciences 24(11):580–88. doi: 10.1016/j.tips.2003.09.011.
Hoyer, Daniel, and Laura H. Jacobson. 2013. ‘Orexin in Sleep, Addiction and More: Is the Perfect Insomnia Drug at Hand?’ Neuropeptides 47(6):477–88. doi: 10.1016/j.npep.2013.10.009.
Kalueff, Allan V., and David J. Nutt. 2007. ‘Role of GABA in Anxiety and Depression’. Depression and Anxiety 24(7):495–517. doi: 10.1002/da.20262.
Kilduff, Thomas S., and Christelle Peyron. 2000. ‘The Hypocretin/Orexin Ligand–Receptor System: Implications for Sleep and Sleep Disorders’. Trends in Neurosciences 23(8):359–65. doi: 10.1016/S0166-2236(00)01594-0.
Levine, Joseph, Daniel P. Cole, K. N. Roy Chengappa, and Samuel Gershon M.D. 2001. ‘Anxiety Disorders and Major Depression, Together or Apart’. Depression and Anxiety 14(2):94–104. doi: 10.1002/da.1051.
Luscher, B., Q. Shen, and N. Sahir. 2011. ‘The GABAergic Deficit Hypothesis of Major Depressive Disorder’. Molecular Psychiatry 16(4):383–406. doi: 10.1038/mp.2010.120.
Mahowald, Mark W., and Carlos H. Schenck. 1992. ‘Dissociated States of Wakefulness and Sleep’. Neurology 42 Suppl. 6:44–52.
Mark W. Mahowald MD. 2007. ‘Pathophysiologic Mechanisms in REM Sleep Behavior Disorder’. Current Neurology and Neuroscience Reports 7(Issue 2):167–72. doi: 10.1007/s11910-007-0013-7.
N.P. Robertson, K. J. Peall. 2014. ‘Narcolepsy: Environment, Genes and Treatment’. 261(8):1644–46.
Saper, Clifford B., and Thomas E. Scammell. 2013. ‘Emerging Therapeutics in Sleep’. Annals of Neurology 74(3):435–40. doi: 10.1002/ana.24000.
Smith, Kiersten S., and Uwe Rudolph. 2012. ‘Anxiety and Depression: Mouse Genetics and Pharmacological Approaches to the Role of GABAA Receptor Subtypes’. Neuropharmacology 62(1):54–62. doi: 10.1016/j.neuropharm.2011.07.026.
Stores, G. 2003. ‘Medication for Sleep-Wake Disorders’. Archives of Disease in Childhood 88(10):899–903. doi: 10.1136/adc.88.10.899.
Strange, P. G. 1992. Brain Biochemistry and Brain Disorders. Oxford: Oxford University Press.
